Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate plasma and target site concentrations derived from their established human pharmacokinetics (2020)
Attributed to:
Tropical Infectious Disease Consortium: Expanding and Accelerating Product
Development
funded by
UKRI
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1101/2020.04.16.20068379
Publication URI: http://dx.doi.org/10.1101/2020.04.16.20068379
Type: Preprint